/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer
S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer

OncLive® On Air · Oct 16, 2026

FDA approves tucatinib plus HP maintenance for HER2+ advanced breast cancer, extending median PFS by 8.6 months regardless of HR status.

Omission of Endocrine Therapy During HER2 Maintenance Persists Despite Clear Survival Advantages

In the HER2CLIMB-05 trial, 55% of patients with ER-positive tumors did not receive concurrent endocrine therapy despite study protocol allowances. Dr. Hamilton noted that those who received endocrine therapy achieved much longer progression-free survival, highlighting a crucial treatment opportunity during chemotherapy de-escalation.

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer thumbnail

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer

OncLive® On Air·a month ago

Tucatinib Maintenance Toxicities Stem Primarily From Elevated LFTs Rather Than Compounded Diarrhea

Despite initial concerns that combining pertuzumab and tucatinib would exacerbate severe diarrhea, grade 3 diarrhea increased by only 2% over placebo. Rather than gastrointestinal issues, elevated liver function tests occurred in approximately 25% of patients and served as the leading driver of dose holds, reductions, and treatment discontinuations.

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer thumbnail

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer

OncLive® On Air·a month ago

Oncologists Plan Off-Label Tucatinib Maintenance After Reaching Maximal Response on TDxD

Although the DESTINY-Breast09 trial omitted a maintenance phase following trastuzumab deruxtecan and pertuzumab, Dr. Hamilton notes oncologists will likely transition patients off therapy upon reaching maximal response. Clinicians expect to integrate tucatinib maintenance without randomized data to support long-term quality of life.

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer thumbnail

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer

OncLive® On Air·a month ago